Clinical Trial Update: Akt Inhibitor MK2206 and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors, Melanoma, Prostate or Kidney Cancer [Phase 1]

View source ↗

Summary

Phase 1 trial update on MK-2206 plus hydroxychloroquine for advanced solid tumors, including melanoma, prostate cancer, and renal cell carcinoma; study status i…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma
• Prostate Cancer
• Renal Cell Carcinoma

Drugs mentioned

• Hydroxychloroquine (hydroxychloroquine)
• MK-2206 (MK-2206)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Advanced Malignant Solid Neoplasm, Stage III Cutaneous Melanoma AJCC v7 | Phase 1 | Status: ACTIVE_NOT_RECRUITING